Quoin Pharmaceuticals, Ltd.
QNRXNasdaq
$4.24
↑ +1.9%Jul 17 close · end-of-day
Price
1Y↓ -50.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
—
Enterprise Value
—
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$17.0M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-193.6%
ROIC
—
Debt / Equity
—
Net Cash
$14.0M
Return 1Y
-51.5%
Company profile
Quoin Pharmaceuticals, Ltd. focuses on the development of therapeutic products for rare and orphan diseases. It offers QRX003, a topical lotion to treat Netherton Syndrome; QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease.
- CEO
- Michael Myers
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 4
- Website
- quoinpharma.com
Earnings
QNRX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS——
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | — | — | — | — | — | — |
| Net income | -$2.1M | -$21.5M | -$9.4M | -$8.7M | -$9.0M | -$15.8M |
| Diluted EPS | -$0.70 | -$0.01 | — | — | — | — |
| Operating cash flow | -$1.3M | -$5.7M | -$8.5M | -$7.9M | -$7.9M | -$13.5M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q3 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q3 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | — | — | — | — | — | — | — | — |
| Net income | -$2.0M | -$2.3M | -$2.3M | -$3.8M | -$3.7M | -$3.9M | -$4.3M | -$5.0M |
| Diluted EPS | — | — | — | — | — | — | — | — |
| Operating cash flow | -$2.0M | -$2.2M | -$2.2M | -$2.6M | -$3.7M | -$2.2M | -$5.0M | -$4.9M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-10-14 | LANGER DENNIS | Buy | 15,152 | $8.49 | $128,640.48 | filing |
Latest 1 transaction.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.